|
An association between proton-pump inhibitor (PPI) use and hip fracture has been shown.
The mechanism by which proton-pump inhibitor use promotes the development of hip fracture is uncharacterized.
Dr Laura Targownik and colleagues from Canada determined whether proton-pump inhibitor use is associated with osteoporosis or accelerated bone mineral density loss.
The team used the Manitoba Bone Mineral Density Database to determine the relationship between chronic proton-pump inhibitor use and osteoporosis on an initial assessment of bone mineral density, and on bone mineral density loss between successive assessments of bone mineral density.
In the cross-sectional study, cases with osteoporosis at the hip or lumbar vertebrae were matched to 3 controls with normal bone mineral density.
 | | PPI use was not associated with having osteoporosis at hip | | Gastroenterology |
In the longitudinal analysis, the change in bone mineral density among proton-pump inhibitor users and nonusers between successive bone mineral density assessments was assessed.
The team used regression analysis to obtain estimates of the association between proton-pump inhibitor use and osteoporosis and of the annualized change in bone mineral density associated with proton-pump inhibitor use.
The researchers found proton-pump inhibitor use was not associated with having osteoporosis at either the hip or the lumbar spine for proton-pump inhibitor use over 1500 doses over the previous 5 years.
The research team observed no significant decrease in bone mineral density at either site attributable to proton-pump inhibitor use.
Dr Targownik's team concluded, “Proton-pump inhibitor use does not appear to be associated with either the presence of osteoporosis or accelerated bone mineral density loss.”
“The association between proton-pump inhibitor use and hip fracture is probably related to factors independent of osteoporosis.”
| 
Email this page to a colleague
